lignans has been researched along with Hyperlipidemias* in 8 studies
1 review(s) available for lignans and Hyperlipidemias
Article | Year |
---|---|
Availability of bioactive flax lignan from foods and supplements.
Hyperlipidemia, high levels of blood lipids including cholesterol and triglycerides, is a major risk factor for cardiovascular disease. Traditional treatments of hyperlipidemia often include lifestyle changes and pharmacotherapy. Recently, flaxseed has been approved as a nutrient that lowers blood lipids. Several metabolites of flaxseed lignan secoisolariciresinol diglucoside (SDG), have been identified that reduce blood lipids. SDG is present in flaxseed hull as an ester-linked copolymer with 3-hydroxy-3-methylglutaric acid (HMGA). However, purification processes involved in hydrolysis of the copolymer and enriching SDG are often expensive. The natural copolymer of SDG with HMGA (SDG polymer) is a source of bioactive compounds useful in prophylaxis of hypercholesterolemia. After consumption of the lignan copolymer, SDG and HMGA are released in the stomach and small intestines. SDG is metabolized to secoisolariciresinol, enterolactone and enterodiol, the bioactive forms of mammalian lignans. These metabolites are then distributed throughout the body where they accumulate in the liver, kidney, skin, other tissues, and organs. Successively, these metabolites reduce blood lipids including cholesterol, triglycerides, low density lipoprotein cholesterol, and lipid peroxidation products. In this review, the metabolism and efficacies of flaxseed-derived enriched SDG and SDG polymer will be discussed. Topics: Animals; Cholesterol; Flax; HMGA Proteins; Humans; Hyperlipidemias; Lignans; Lipids; Mammals; Polymers; Triglycerides | 2023 |
7 other study(ies) available for lignans and Hyperlipidemias
Article | Year |
---|---|
Flaxseed oil stimulates gynecomastia.
Flaxseed oil contains lignans, which exhibit anti-inflammatory and antiatherogenic activities. A 70-year-old male patient presented to our office due to hyperlipidaemia and started to take a tablespoon of flaxseed oil daily. Three months later, he reported left breast swelling and pain. Although the echogram revealed a tumour in the left mammary gland, the breast biopsy was compatible with gynecomastia, showing ductal hyperplasia without evidence of malignancy. His breast epithelia were oestrogen receptor-positive. Potential role of phytoestrogens was discussed. Topics: Aged; Gynecomastia; Humans; Hyperlipidemias; Lignans; Linseed Oil; Male; Phytoestrogens | 2020 |
Magnolol Alleviates Inflammatory Responses and Lipid Accumulation by AMP-Activated Protein Kinase-Dependent Peroxisome Proliferator-Activated Receptor α Activation.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Biphenyl Compounds; Fatty Liver; Hep G2 Cells; Humans; Hyperlipidemias; Lignans; Lipid Metabolism; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Oleic Acid; PPAR alpha | 2018 |
Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice.
Schisandra, a globally distributed plant, has been widely applied for the treatment of diseases such as hyperlipidemia, fatty liver and obesity in China. In the present work, a rapid resolution liquid chromatography coupled with quadruple-time-of-flight mass spectrometry (RRLC-Q-TOF-MS)-based metabolomics was conducted to investigate the intervention effect of Schisandra chinensis lignans (SCL) on hyperlipidemia mice induced by high-fat diet (HFD).. Hyperlipidemia mice were orally administered with SCL (100 mg/kg) once a day for 4 weeks. Serum biochemistry assay of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) was conducted to confirm the treatment of SCL on lipid regulation. Metabolomics analysis on serum samples was carried out, and principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were carried out for the pattern recognition and characteristic metabolites identification. The relative levels of critical regulatory factors of liver lipid metabolism, sterol regulatory element-binding proteins (SREBPs) and its related gene expressions were measured by quantitative real-time polymerase chain reaction (RT-PCR) for investigating the underlying mechanism.. Oral administration of SCL significantly decreased the serum levels of TC, TG and LDL-c and increased the serum level of HDL-c in the hyperlipidemia mice, and no effect of SCL on blood lipid levels was observed in control mice. Serum samples were scattered in the PCA scores plots in response to the control, HFD and SCL group. Totally, thirteen biomarkers were identified and nine of them were recovered to the normal levels after SCL treatment. Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis, the anti-hyperlipidemia mechanisms of SCL may be involved in the following metabolic pathways: tricarboxylic acid (TCA) cycle, synthesis of ketone body and cholesterol, choline metabolism and fatty acid metabolism. Meanwhile, SCL significantly inhibited the mRNA expression level of hepatic lipogenesis genes such as SREBP-1c, fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), and decreased the mRNA expression of liver X receptor α (LXRα). Moreover, SCL also significantly decreased the expression level of SREBP-2 and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in the liver of hyperlipidemia mice.. Anti-hyperlipidemia effect of SCL was confirmed by both serum biochemistry and metabolomics analysis. The mechanism may be related to the down-regulation of LXRα/SREBP-1c/FAS/ACC and SREBP2/HMGCR signaling pathways. Topics: Animals; Biomarkers; Cholesterol; Diet, High-Fat; Hyperlipidemias; Lignans; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mice, Inbred C57BL; Principal Component Analysis; RNA, Messenger; Schisandra; Sterol Regulatory Element Binding Proteins; Triglycerides | 2017 |
Physiological effects of γ-linolenic acid and sesamin on hepatic fatty acid synthesis and oxidation.
Interrelated effects of γ-linolenic acid (GLA) and sesamin, a sesame lignan, on hepatic fatty acid synthesis and oxidation were examined. Rats were fed experimental diets supplemented with 0 or 2 g/kg sesamin (1:1 mixture of sesamin and episesamin) and containing 100 g/kg of palm oil (saturated fat), safflower oil rich in linoleic acid, or oil of evening primrose origin containing 43% GLA (GLA oil) for 18 days. In rats fed sesamin-free diets, GLA oil, compared with other oils, increased the activity and mRNA levels of various enzymes involved in fatty acid oxidation, except for some instances. Sesamin greatly increased these parameters, and the enhancing effects of sesamin on peroxisomal fatty acid oxidation rate and acyl-CoA oxidase, enoyl-CoA hydratase and acyl-CoA thioesterase activities were more exaggerated in rats fed GLA oil than in the animals fed other oils. The combination of sesamin and GLA oil also synergistically increased the mRNA levels of some peroxisomal fatty acid oxidation enzymes and of several enzymes involved in fatty acid metabolism located in other cell organelles. In the groups fed sesamin-free diets, GLA oil, compared with other oils, markedly reduced the activity and mRNA levels of various lipogenic enzymes. Sesamin reduced all these parameters, except for malic enzyme, in rats fed palm and safflower oils, but the effects were attenuated in the animals fed GLA oil. These changes by sesamin and fat type accompanied profound alterations in serum lipid levels. This may be ascribable to the changes in apolipoprotein-B-containing lipoproteins. Topics: Acyl-CoA Oxidase; Animals; Dietary Fats, Unsaturated; Dietary Sucrose; Dietary Supplements; Dioxoles; Enoyl-CoA Hydratase; Fatty Acids; gamma-Linolenic Acid; Gene Expression Regulation, Enzymologic; Hyperlipidemias; Hypolipidemic Agents; Lignans; Linoleic Acids; Lipids; Liver; Male; Oenothera biennis; Oxidation-Reduction; Palm Oil; Peroxisomes; Plant Oils; Rats, Sprague-Dawley; Safflower Oil; Thiolester Hydrolases | 2017 |
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia. Here, a novel mouse model of combined hyperlipidemia is described. Mice were orally given a single dose of a modeling agent (MA) made of a mixture of schisandrin B/cholesterol/bile salts (1/2/0.5 g/kg) suspended in olive oil. MA treatment increased serum triglycerides (TG) and total cholesterol (TC) (up to 422% and 100% at 12 - 96 h post-treatment, respectively) and hepatic TG and TC (up to 220% and 26%, respectively) in a time- and dose-dependent manner, associated with elevation of high-density lipoprotein and low-density lipoprotein levels. Serum alanine/aspartate aminotransferase activities, indicators of liver cell damage, were also elevated (up to 198%) at 48 and 72 h post-MA treatment. Fenofibrate blocks MA-induced hyperlipidemia, lipid accumulation in the liver, as well as liver injury. Oral administration of a mixture of schisandrin B, cholesterol, and bile salt could generate an interesting mouse model of combined hyperlipidemia associated with hepatic steatosis and steatohepatitis. Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholesterol; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Hyperlipidemias; Lignans; Lipoproteins; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Time Factors; Triglycerides | 2013 |
Effects of the flaxseed lignans secoisolariciresinol diglucoside and its aglycone on serum and hepatic lipids in hyperlipidaemic rats.
The present study involved a comparative analysis of the effects of purified flaxseed lignans, secoisolariciresinol diglucoside (SDG) and its aglycone metabolite (SECO), in hyperlipidaemic rats. For hypercholesterolaemia, female Wistars (six rats per group) were fed a standard or 1 % cholesterol diet and orally administered 0, 3 or 6 mg SDG/kg or 0, 1.6 or 3.2 mg SECO/kg body weight once daily for 4 weeks. Hypertriacylglycerolaemia was induced in male Sprague-Dawley rats (ten rats per group) by supplementing tap water with 10 % fructose. These rats were orally administered 0, 3 or 6 mg SDG/kg body weight once daily for 2 weeks. Fasting blood samples (12 h) were collected predose and at the end of the dosing period for serum lipid analyses. Rats were killed and livers rapidly excised and sectioned for lipid, mRNA and histological analyses. Chronic administration of equimolar amounts of SDG and SECO caused similar dose-dependent reductions in rate of body-weight gain and in serum total and LDL-cholesterol levels and hepatic lipid accumulation. SDG and SECO failed to alter hepatic gene expression of commonly reported regulatory targets of lipid homeostasis. SDG had no effect on serum TAG, NEFA, phospholipids and rate of weight gain in 10 % fructose-supplemented rats. In conclusion, our data suggest that the lignan component of flaxseed contributes to the hypocholesterolaemic effects of flaxseed consumption observed in humans. Future studies plan to identify the biochemical mechanism(s) through which flaxseed lignans exert their beneficial effects and the lignan form(s) responsible. Topics: Animals; Base Sequence; Body Weight; Butylene Glycols; Dose-Response Relationship, Drug; Female; Flax; Fructose; Gene Expression; Glucosides; Hyperlipidemias; Lignans; Lipids; Liver; Male; Models, Animal; Molecular Sequence Data; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2009 |
Protective role of flax lignans against lead acetate induced oxidative damage and hyperlipidemia in rats.
The results showed that the lead concentration was higher than Cr, Ni and Cd in roadside soil samples. Also, the present study was conducted to investigate the protective role of flax lignans against the effects of lead acetate on oxidative stress, antioxidant enzymes and lipid profile. Animals were divided into three groups; the first group was used as control. While, groups 2, and 3 were orally treated with 200 mg/L lead acetate in drinking water and the combination of lead acetate (200 mg/L) plus flax lignans (30 mg/100 g BW), respectively. Rats were administered their respective doses daily for 3 weeks. Results showed that lead acetate increased TBARS, and decreased the activities of GST, SOD, GR and CAT, and the contents of glutathione in liver extracts, compared to control. The present data indicated that total lipids, cholesterol, triglycerides and LDL-c were significantly increased by lead acetate treatment, while HDL-c levels were decreased in the serum and liver extracts. Animals treated with flax lignans in combination with lead acetate alleviated its toxic effects in the tested parameters. Also, the morph metric analysis of the dorsal aorta revealed that, the histological alterations induced after lead acetate treatments were markedly reduced. Topics: Animals; Cholesterol, LDL; Female; Flax; Glutathione Transferase; Hyperlipidemias; Lignans; Lipid Peroxidation; Organometallic Compounds; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Soil Pollutants | 2009 |